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Background: Neutrophil gelatinase associated lipocalin (NGAL) is a highly predictive biomarker of acute kidney
injury. To understand the role of NGAL in renal injury during sepsis, we investigated the temporal changes and
biological sources of NGAL in a rat model of acute kidney injury, and explored the relationship between renal
inflammation, humoral NGAL and NGAL expression during endotoxemia.
Methods: To induce acute renal injury, rats were treated with lipopolysaccharide (LPS, 3.5 mg/kg, ip), and the
location of NGAL mRNA was evaluated by in situ hybridization. Quantitative RT-PCR was also used to determine the
dynamic changes in NGAL, tumor necrosis factor α (TNFα) and interleukin (IL)-6 mRNA expression 1, 3, 6, 12, and 24
hours following LPS treatment. The correlation among NGAL, TNFα and IL-6 was analyzed. Urinary and plasma
NGAL (u/pNGAL) levels were measured, and the relationship between humoral NGAL and NGAL expression in the
kidney was investigated.
Results: Renal function was affected 3–12 hours after LPS. NGAL mRNA was significantly upregulated in tubular
epithelia at the same time (P< 0.001). The course of NGAL mRNA upregulation occurred in parallel with renal
damage. There was a transient increase in TNFα and IL-6 mRNA levels within 3 hours following LPS administration,
and a strong correlation between TNFα and NGAL mRNA (r = 0.995, P <0.001) but not with IL-6 mRNA. Both pNGAL
and uNGAL levels were markedly increased compared with those in the control group (P< 0.001); however, only
uNGAL levels were correlated with NGAL mRNA (r = 0.850, P <0.001).
Conclusions: NGAL upregulation is sensitive to LPS-induced renal TNFα increase and injury, which are observed in
the tubular epithelia. Urinary NGAL levels accurately reflect changes in NGAL in the kidney.
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Acute kidney injury (AKI; or acute renal failure) is an
important issue for patients during critical care, with
sepsis being the most common trigger for AKI in the in-
tensive care unit (ICU) [1-3]. Because of the lack of sen-
sitive and specific biomarkers for indicating renal cell
injury, the mortality rates for septic AKI have remained
high [1,4]. Recently, genomic, transcriptomic, and prote-
omic techniques have identified neutrophil gelatinase
associated lipocalin (NGAL) as an early marker of AKI
[5,6]. NGAL has been investigated in a range of different* Correspondence: yinglihebei@163.com
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reproduction in any medium, provided the orclinical settings, such as contrast-induced nephropathy,
AKI after cardiac surgery or kidney transplantation and
AKI in the critical care setting. Overall, the sensitivity for
NGAL to predict AKI is 0.815 (95 % confidence interval,
0.732-0.892) and it is a promising biomarker for AKI,
similar to troponin for acute myocardial infarction [7].
However, the use of NGAL in detecting or predicting
the outcomes of patients with septic AKI is complex and
depends on the clinical setting. In previous research of
critically ill patients [8,9], both serum NGAL (sNGAL)
and plasma NGAL (pNGAL) levels have the potential to
act as early biomarkers for AKI. While both of them are
highly sensitive, they have not been found to be very spe-
cific predictors of septic AKI. Shapiro et al. assessed the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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wherein it was revealed that pNGAL concentrations of
>150 ng/mL were 96 % sensitive but only 51 % specific
for patients with suspected septic AKI[9]. Martensson
et al. observed that pNGAL is elevated in patients with
systemic inflammatory response syndrome, severe sepsis,
and septic shock, and it should be used with caution as a
marker of AKI in ICU patients with septic shock [10]. In
contrast, studies have shown that urinary NGAL
(uNGAL) is more useful for predicting AKI, as uNGAL
levels are not elevated in septic patients without AKI.
Understanding the role of NGAL in impaired renal tis-
sues may help clarify this issue.
Furthermore, a biomarker should temporally reflect the
pathophysiology initiated by a stimulus leading to injury
so as to alert the clinician to a potentially reversible stage
of the illness. In the case of septic AKI, the relationship be-
tween NGAL and early inflammation mechanisms in the
kidney will ought to be clearly established. However, the
mechanisms of septic AKI remain undefined. Increasing
evidence suggests that intrarenal inflammatory mediators
play an important role in the pathogenesis of kidney injury
[11-14]. Specially, tumor necrosis factor α (TNFα) is a
pivotal proinflammatory mediator and interleukin (IL)-6 is
an accessory factor [15,16]. However, it remains unknown
whether NGAL expression is related to changes in renal
IL-6 and TNFα during the early stage of septic AKI.
Based on the available evidence, the use of NGAL as a
marker of septic AKI is promising but requires further
investigation. In particular, the relationship between
NGAL expression, humoral NGAL and renal inflamma-
tion requires additional clarification. However, few stud-
ies have specifically investigated the expression of NGAL
in renal tissues during sepsis. Therefore, the purpose of
this study was to investigate the pattern and localization
of renal NGAL expression, and to explore the relation-
ship between renal inflammation mediators, such as
TNFα and IL-6, and humoral NGAL in a rat model of
lipopolysaccharide (LPS)-induced kidney injury.
Methods
Animals
Male Sprague–Dawley rats (Animal Laboratory of Hebei
Medical University), 200-220 g, were used in this study.
The rats were maintained for a 3-day period before the
experimental procedure under a 12-h light/dark cycle at
a constant temperature (23 ± 2°C), with free access to
food and tap water. All animal experiments were in com-
pliance with the guidelines stated by the Institutional
Animal Care and Use Committee.
Experimental groups
Endotoxemia and AKI were induced in the rats by inject-
ing them intraperitoneally (i.p.) with LPS (Escherichiacoli 0111: B4, Sigma-Aldrich). The LPS was dissolved in
a concentration of 1 mg/ml in normal saline. Since the
response to LPS is strongly dependent on ambient
temperature [17], the environmental temperature was
maintained at 24°C.
The rats were randomly assigned into six groups (n = 8
rats/group). Group 1, the control group, was treated with
isometric sterile saline. Groups 2 to 6 were treated with
LPS (3.5 mg/kg body weight). Differences between
Groups 2 to 6 reflected the different time points follow-
ing LPS administration at which sampling was conducted
(1, 3, 6, 12 and 24 h). Urine was gathered via metabolic
cages and the supernatant was obtained and collected.
The animals were then anaesthetized with sodium pento-
barbital (60 mg/kg i.p.), and 2 ml of blood was obtained
by cardiac puncture and processed to collect plasma and
serum samples, which were frozen at −80°C for subse-
quent use [18]. The kidneys were also harvested. Half of
the kidney was fixed in paraformaldehyde and processed
for hematoxylin and eosin (H&E) staining and in situ
hybridization, and the other half was snap-frozen in li-
quid nitrogen and stored at −80°C for subsequent bio-
chemical analysis.Evaluating renal function
Renal function, in the form of serum creatinine levels,
was evaluated in the saline- and LPS-treated animals
using a colorimetric assay (Creatinine Assay Kit; Biosino
Bio-Technology). The serum creatinine levels were eval-
uated by measuring the change in absorbance over 40
seconds in the experimental samples relative to the
standards.Histological studies
Histopathology was conducted on the kidney samples to
determine the time-course of renal micro-morphological
injury in the LPS-induced endotoxemia rats. Each sam-
ple of kidney (one quarter from both the control and ex-
perimental groups) was fixed in 4 % paraformaldehyde,
dehydrated in graded ethanol and embedded in paraffin
as previously described [19]. Each paraffin block was
processed into 5-μm-thick slices that were H&E-stained.
A portion (~1 mm3) of renal cortex from each rat was
fixed in 2.5 % glutaraldehyde diluted in 0.066 M phos-
phate buffer (pH 7.4) for 24 hours. The samples were
then dehydrated in a graded ethanol series and embed-
ded in Epon 812 resin at 60°C for 48 hours. Thin sec-
tions (50 nm) were then double-stained with uranyl
acetate and lead citrate, and were observed and photo-
graphed with a transmission electron microscope oper-
ated at 80 kV. The epithelial layer was examined and
photographed with a transmission electron microscope
(Hitachi, H-7500, TEM) at a magnification of 5000×.





GAPDH GGCATGGACTGTGGTCATGA TTCACCACCATGGA GAAGGC
Abbreviations: NGAL, neutrophil gelatinase associated lipocalin; TNFα, tumor
necrosis factor α; IL-6, interleukin 6; GAPDH as a housekeeping gene.
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In situ hybridization was performed on 5-μm sections
using an acetylcholine receptor in situ hybridization Kit
(BioChain Institute, Hayward, CA) with some modifica-
tions to the instructions provided by the manufacturers.





hydration, and antigen retrieval were performed as previ-
ously described [20]. The sections were then incubated in
diethyl pyrocarbonate (0.1 % DEPC)-treated PBS and fixed
in 4 % paraformaldehyde in PBS for 10 minutes. After
being rinsed twice with PBS, the slides were prehybridized
with ready-to-use prehybridization solution (20 μl/slice)
for 3 hours at 40°C. The DIG-labeled probe (0.15 μg/μl)
was diluted to 20 ng/μl in ready-to-use hybridization buffer
and applied to the prehybridized tissues. The sections then
were incubated at 40°C for 16 hours. Posthybridization, the
sections were washed and incubated for 2 hours in AP-
conjugated anti-DIG antibodies (1:100, diluted in PBS).
After the staining was developed, the reaction was stopped
by incubating the slides in 10 mM Tris buffer (pH 8.0,
1 mM EDTA). Finally, the slides were rinsed in distilled
H2O, counterstained with sappan wood, dehydrated with
alcohol, transparented with xylene, and then sealed to take
images with a dissecting microscope (Olympus, cx31).
RNA extraction and quantitative reverse-transcription
polymerase chain reaction (qRT-PCR)
RNA was extracted from the kidney samples using a sin-
gle-step RNA isolation method [21] with the Total Quick
RNA kit (D9108B; TaKaRa, Dalian, China). The purified
RNA (500 ng) was quantified and reverse-transcribed
using the PrimeScript RT reagent kit (DRR037A; TaKaRa,
Dalian, China), according to the manufacturer’s instruc-
tions, yielding 20 μl of first-strand cDNA. The qRT-PCR
experiments were measured on an ABI Prism 7500 RT-
PCR machine (Applied Biosystems, Carlsbad, CA, USA).
The different mRNA expression levels were then calcu-
lated and expressed as the number of copies per reaction.
All experiments were performed in triplicate. The fold
change in mRNA levels of each gene was calculated using
the △ △CT method. The mRNA levels were normalized
by using GAPDH as a housekeeping gene, and they were
compared with the control group. The authenticity and
size of the PCR products were confirmed by 2 % agarose
gel electrophoresis imprinting. The primers used for amp-
lification are listed in Table 1.
Plasma and urine NGAL concentrations
Plasma and urine samples were obtained from the rats at
1, 3, 6, 12, and 24 hours after the LPS (or saline)treatment, and the concentration of NGAL was deter-
mined using a commercially available ELISA kit (CSB-
E09409r, Cusabio Biotech, China), in accordance with
the manufacturer’s instructions. Briefly, microtiter plates
pre-coated with a goat polyclonal antibody raised against
rat NGAL were incubated in blocking buffer containing 1 %
BSA, and then coated with 100 μL samples of either plasma,
urine or NGAL standards (ranging from 1–200 ng/mL).
The plates were then incubated with a horseradish peroxid-
ase conjugated, affinity purified rabbit anti-goat IgG anti-
body, and a TMB substrate was added for color
development. The plates were then read within 30 minutes
(450 nm) with a Benchmark Plus microplate reader (Bio-
Tek Instruments Inc., Winooski, VT, USA). All measure-
ments were performed in triplicate.
Statistical analysis
All values are expressed as mean±SEM. The data were
normally distributed, as determined using a Kolmogorov-
Smirnov test. Comparisons among groups were conducted
with one-way ANOVA. When the F value was significant
(P< 0.05), the Student–Newman–Keuls Test and least sig-
nificant difference procedure were performed to test for
differences between the means. We used simple regression
analysis after log transformation to evaluate whether the
values were correlated. A P value of less than 0.05 was
considered to be significant.
Results
LPS-induced AKI
Rats treated with LPS showed significantly elevated levels
of serum creatinine, which were significantly increased
from 3 to 12 hours after LPS administration compared
with those in the control group (P< 0.001, Figure 1A).
Histopathology was also performed to determine the
time-course of renal damage following LPS treatment.
The kidneys from the control group showed normal
glomeruli and tubules. In contrast, the kidneys of the
LPS-treated rats were characterized by transient renal
damage. Under a light microscope, there were no intrin-
sic lesions within the glomeruli, but lesions consisting of
epithelial swelling were observed in the 3–12-hour
groups. Further, intracellular edema was also detected
and was more severe in the straight segment of the
Figure 1 SCr and renal histological injury in rats subjected to LPS at different time points. A, SCr levels are shown, with the mean values/
group obtained by colorimetric assay (uM/L). There was a significant increase in SCr levels in rats at 3, 6 and 12 hours. B, Renal histology under
light microscopy and TEM at 6 hours following LPS treatment (H&E, 200×; TEM, 5000×) are shown. The arrows indicate intracellular edema,
inflammatory cell infiltration, microvilli in disarray, or injury to the mitochondrial outer membrane. Abbreviations: SCr = serum creatinine.
**P< 0.001, relative to the control group.
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analysis further demonstrated the presence of intracellu-
lar edema, coupled with disarranged microvilli, and/or
injury or destruction of the mitochondrial outer mem-
brane in the proximal epithelia (Figure 1B).
On the basis of changes to serum creatinine levels and
renal histology, we were able to confirm LPS-induced
AKI, and thus confirm that we had established a suitable
animal model.Upregulation of NGAL gene expression in the tubular
epithelia
Using in situ hybridization analysis, we observed weak
NGAL mRNA expression in the distal tubular epithelia
and medullary collecting ducts of the control kidneys;
however, NGAL mRNA expression was not detected by
qRT-PCR. In contrast, 24.3-49.6 % of the tubular cells,
including the proximal epithelia, were NGAL mRNA
positive in the kidneys of Groups 2 to 5 (1, 3, 6 and 12
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mRNA expression was significantly decreased in the kid-
neys from Group 6 (24 hours post-LPS treatment)
(Figure 2A). This finding was also confirmed by qRT-PCR,
where LPS-treatment induced the upregulation of renal
NGAL mRNA from 3 to 12 hours following treatment
compared with controls (P< 0.001). More specifically, atC
B
Figure 2 Expression of NGAL mRNA in the LPS-treated rats. A, In situ hyb
in the cortical tubular epithelia in samples in the 3-, 6- and 12-hour LPS group
there was no signal in the controls. B, Relative expression of NGAL mRNA (rela
expresses the intensity of NGAL mRNA in the LPS-treated rats. There was a 12
rising to 226-fold at 6 hours and then it decreased to 162-fold at 12 hours. **Pits peak, the expression of NGAL mRNA increased by
260-fold (Group 4, 6 hours post LPS), and decreased to
23-fold the normal expression levels in Group 6, 24 hours
after LPS-treatment (Figure 2B). The PCR products of
NGAL were confirmed by 2 % agarose gel electrophoresis
imprinting (Figure 2C). These results are similar to previ-
ously published data from a patient study [22].ridization signal time-course. A strong hybridization signal was observed
s compared with a weak signal in the 1- and 24-hour LPS groups, and
tive to the controls) is shown. C, Agarose gel electrophoresis imprinting
9-fold increase in NGAL mRNA expression at 3 hours after LPS treatment,
< 0.001, relative to the control group.
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expression
Plasma and urinary NGAL levels increased soon after
LPS administration. Compared with the control group,
pNGAL levels were markedly increased in experimental
groups and still persisted at high levels in Group 6 (24
hours after administration) (P< 0.001), by which time
the renal damage had disappeared. Peak pNGAL levels
(192.68 ± 14.37 ng/ml) were obtained by 3-hour post-LPS
treatment (Group 3, Figure 3A).
With regard to uNGAL, the LPS-treated rats showed
anuria at the early stages following LPS-treatment. How-
ever, uNGAL levels increased from 3 to 12 hours
(Groups 3, 4 and 5, P< 0.001), and they then decreased
to normal levels in Group 6, 24 hours after LPS-treatment
(P=0.194). Peak uNGAL values (154.42± 12.75 ng/ml)
were observed at the 6-hour time point (Group 4). TheFigure 3 Plasma and urinary NGAL levels in the rats subjected
to LPS-treatment. Data represent the mean± SEM of five
experiments. Abbreviations: pNGAL=plasma NGAL; uNGAL= urinary
NGAL. **P< 0.001, relative to the control group.trends observed for uNGAL levels were similar to the
results of NGAL qRT-PCR analysis, and there was a cor-
relation between the two (r = 0.850, P< 0.001). The correl-
ation between pNGAL and NGAL mRNA in the injured
kidney was not significant (Table 2, Figure 3B).
TNFα and NGAL mRNA are strongly correlated
There was an obvious inflammatory reaction in the kid-
neys following LPS treatment. Both TNFα and IL-6
mRNA expression were significantly increased at the
early stage of LPS-induced AKI (P< 0.001). Specifically,
TNFα mRNA increased by 24-fold in the first hour
(Group 2) and then decreased to baseline levels 3 hours
after treatment (Group 4). Similarly, expression of IL-6
mRNA also increased 24-fold in the first hour (Group 2),
but the expression of IL-6 continued to increase to 68-fold
greater than baseline levels at 3 hours post-treatment
(Group 3), and then decreased to baseline levels at 6 hours
(Group 4). There was a strong correlation between TNFα
and NGAL mRNAs (r = 0.995, P< 0.001), but IL-6 mRNA
was not correlated with NGAL mRNA (Table 2, Figure 4).
Discussion
Almost half of all septic patients develop AKI [23]. Des-
pite advances in treatment strategies for these patients,
mortality due to septic AKI in critically ill patients
remains high, with a mortality rate up to 60 % [3]. Of
those patients that survive, 5-20 % will require dialysis
[24]. The poor clinical outcome of septic AKI patients
partly reflects the lack of knowledge regarding the patho-
physiology of septic AKI. In addition, early diagnosis of
septic AKI with markers of renal function, such as serum
creatinine, which would allow for initiation treatment
regimens before the disease process before becoming
irreversible, are currently inadequate. In response to
these difficulties, there has been a concerted effort to
use high-throughput technologies such as proteomics to
identify novel early biomarkers of AKI. The identification
and study of NGAL marks an important step forward to
identify these biomarkers [25,26]. Human NGAL was
originally identified in neutrophils as a 25 kDa proteinTable 2 Correlation between renal inflammatory factors,




TNFα mRNA 0.995 P< 0.001
IL-6 mRNA 0.276 P= 0.653
uNGAL 0.850 P< 0.001
pNGAL 0.328 P >0.05
Abbreviations: NGAL, neutrophil gelatinase associated lipocalin; TNFα, tumor
necrosis factor α; IL-6, interleukin 6; uNGAL, urinary NGAL; pNGAL, plasma
NGAL.
BFigure 4 Expression of TNFα mRNA and IL-6 mRNA in the LPS-
treated rats. A, Relative expression of TNFα and IL-6 mRNA. LPS
treatment induced upregulation of TNFα and IL-6 mRNA levels,
increasing the expression of both mRNAs by 24-fold at 1 hour
following LPS-treatment, and IL-6 expression rose by 68-fold at 3 hours
post-treatment. B, Agarose gel electrophoresis imprinting for TNFα and
IL-6 mRNA at 1 hour after LPS administration. **P< 0.001, relative to
the TNFα control group; ## P< 0.001, relative to the IL-6 control group.
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9) [27]. Importantly, NGAL fulfills many of the charac-
teristics of a suitable “real-time” renal biomarker. For in-
stance, it has been suggested that serum/urine NGAL
levels, in addition to the intensity of NGAL staining,
may serve as an early biomarker for renal injury follow-
ing kidney transplantation [28-31]. Further, NGAL gene
is also significantly up-regulated in the kidney following
an ischemic insult [5] and has been demonstrated to be
a highly predictive biomarker of other acute and chronic
kidney injuries [32-36].
There are several studies that have analyzed the diag-
nostic and predictive properties of serum, plasma and
urine NGAL in newborn [37] and adult patients criticallyill with septic AKI [10,38,39]. Despite the interest in
NGAL, particularly as a biomarker, there is much uncer-
tainty and divergence regarding its use within the litera-
ture. There are several possible explanations for these
differences. First, NGAL is a member of the lipocalin
superfamily. This is consistent with the role of NGAL as
an endogenous bacteriostatic protein that scavenges bac-
terial siderophores [40]. Therefore, NGAL is significantly
increased in bacterial infections compared with viral
infections [41,42]. Furthermore, increased sNGAL levels
have been reported during systemic disease in the ab-
sence of overt bacterial infection, most notably during
the acute-phase response [43], inflammation [10,44-46],
hypertension [47] and chronic disease [48,49], as well as
during renal tubular injury. It should be noted that
patients with sepsis typically present with co-morbidities.
Because NGAL levels may be influenced by these other
conditions, the adoption of NGAL as a biomarker of
septic AKI must be tempered with caution.
There is limited knowledge of the dynamic changes in
NGAL expression during renal injury, especially in the
case of sepsis-induced renal injury. Therefore, there are
many questions that still need to be answered. One ques-
tion is “Where is the cellular source of NGAL in the
damaged kidney”? In a study by Mori et al. [22], weak
NGAL staining was observed in approximately 10 % of
the total cortical area of the distal tubules, and in the
medullary collecting ducts of the normal kidneys from
healthy volunteers. In contrast, the proximal tubules did
not express NGAL. However, in ischemic or nephrotoxin-
damaged kidneys from patients, nearly 50 % of the cortical
tubules, including the proximal tubules, expressed NGAL.
In a mouse models of renal ischemia-reperfusion injury,
Mishra and colleagues verified that the NGAL protein is
expressed predominantly in the proliferating cell nuclear
antigen-positive proximal tubule cells within 3 hours of is-
chemia [5]. For the first time, we detected NGAL gene ex-
pression in 24.3-49.6 % cortical tubular epithelia, including
proximal epithelia, from 1 to 12 hours following LPS ad-
ministration, which is similar to the findings by Mori and
Mishra. However, in the study of Paragas et al. [50], they
found that NGAL mRNA was not expressed by epithelia
in proximal tubules in the rat at 24 hours after treatment
with lipid A (15 mg/kg, i.p.), but the medullary cells
demonstrated intensive NGAL mRNA expression. These
data described above suggest the following. 1) Different
parts of the kidney have different responses to factors
causing injury, including endotoxin, but overall, the
injured epithelia are the source of NGAL. 2) Epithelia in
proximal tubules might be sensitive to endotoxin, and they
can upregulate the NGAL gene even though the LPS con-
centration is low, but the reactive period is short. Thus,
NGAL expression can be detected in the early stage after
LPS administration, and then decrease to baseline levels.
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and they will not become active until they face a high con-
centration of LPS. However, they can increase NGAL ex-
pression longer than the cells in proximal tubules.
Moreover, the relationship between NGAL in renal in-
jury and humoral NGAL needs to be clarified. Paragas
and colleagues [45] verified that uNGAL originates in
the kidney from results of cross-transplants between
NGAL knockout and wild-type mice, followed by renal
artery clamping. They found that NGAL is present in the
kidney, liver, spleen, lung and trachea after lipid A treat-
ment, which indicates that NGAL in the blood is not a
good marker of septic AKI [50]. Our study revealed, for
the first time, the pattern of renal NGAL expression dur-
ing the early stage of endotoxemia. We found that renal
NGAL could be a useful biomarker of renal epithelia in-
jury. In particular, uNGAL exactly reflected the change
in renal NGAL expression, whereas pNGAL was not as
accurate in septic AKI. Therefore, based on the findings
of these studies, it appears that uNGAL levels are related
to NGAL gene expression in the kidney, and uNGAL
has the ability to act as a marker for the diagnosis and
monitoring of AKI in patients with sepsis. This could
lead to renoprotective therapies and avoidance of renal
injury. However, pNGAL or sNGAL levels may be mis-
leading in the diagnosis of septic AKI. Misdiagnosis may
result in conservative strategies and the optimal thera-
peutic time in critically ill patients may be missed.
Sepsis is associated with the production of many in-
flammatory mediators, including TNFα [51,52]. TNFα is
released first when sepsis occurs and leads to cleavage of
the nuclear factor κB (NF-κB) inhibitor. Once this inhibi-
tor is removed, NF-κB is able to initiate the production
of mRNA, which induces the production of other proin-
flammatory cytokines, chemokines, and adhesion mole-
cules [53]. For instance, Knotek et al. demonstrated that
TNFα is a critical mediator of endotoxin-induced sepsis,
and that TNFα inhibition prevents physiological changes
and morbidities associated with LPS administration in
wild-type and inducible nitric oxide synthase knockout
mice [54]. Therefore, TNFα is a key mediator of LPS-
induced acute renal failure, acting through its receptor,
TNFR1 [55]. Early changes in renal TNFα mRNA levels
after endotoxemia have not been reported. In our study,
we found that TNFα mRNA was induced by 24-fold
within 3 hours after LPS treatment. The result of our
study also confirm the findings of Wang and colleagues,
they showed that LPS induced TNF-α protein by 24-fold
in the kidney 16 hours after administration[14]. Further-
more, for the first time, we showed that NGAL mRNA
was related to TNFα mRNA levels in the injured kidney,
and that NGAL mRNA upregulation closely followed
TNFα mRNA increase, similar to a down-regulation
cytokine in the inflammation cascade. Previous studies[22,50] have found that NGAL is suppressed by the NF-
κB inhibitor in primary kidney cells after lipid A admin-
istration, and that the NGAL:siderophore:Fe complex
preserves proximal tubule N-cadherin and inhibits cell
death. Therefore, is it possible that TNFα/NF-κB/NGAL
is an important mechanism for regulating tubular cells
by increasing proliferation and/or inducing/suppressing
apoptosis during sepsis? This possibility should be inves-
tigated in future studies.
Conclusions
The upregulation of NGAL gene expression in the tubu-
lar epithelia occurs after LPS-treatment, and this finding
is coupled with the observation of renal TNFα increase
and injury. Urinary NGAL levels accurately reflect the
changes in NGAL mRNA in this kidney injury model.
Competing interests
The authors have no competing interests to declare.
Author details
1Department of Nephropathy, The Third Hospital of Hebei Medical University,
Shijiazhuang 050051, China. 2Department of Forensic Medicine, Hebei
Medical University, Shijiazhuang 050051, China.
Authors’ contributions
MH collected samples, performed the histology and in situ hybridization
analysis, performed the qRT-PCR and ELISA, and wrote and edited the
manuscript. YL coordinated the in vivo studies and edited the manuscript.
MDL coordinated the in vitro studies and edited the manuscript. YML and BC
edited the manuscript. All authors read and approved the final manuscript.
Received: 4 January 2012 Accepted: 7 May 2012
Published: 7 May 2012
References
1. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz
M, Tan I, Bouman C, Macedo E, et al: Acute renal failure in critically ill
patients: a multinational, multicenter study. Jama 2005, 294(7):813–818.
2. Medve L, Antek C, Paloczi B, Kocsi S, Gartner B, Marjanek Z, Bencsik G,
Kanizsai P, Gondos T: Epidemiology of acute kidney injury in Hungarian
intensive care units: a multicenter, prospective, observational study. BMC
Nephrol, 12:43.
3. Parmar A, Langenberg C, Wan L, May CN, Bellomo R, Bagshaw SM:
Epidemiology of septic acute kidney injury. Curr Drug Targets 2009, 10
(12):1169–1178.
4. Matejovic M, Chvojka J, Radej J, Ledvinova L, Karvunidis T, Krouzecky A,
Novak I: Sepsis and acute kidney injury are bidirectional. Contrib Nephrol,
174:78–88.
5. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan
P: Identification of neutrophil gelatinase-associated lipocalin as a novel
early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003,
14(10):2534–2543.
6. Supavekin S, Zhang W, Kucherlapati R, Kaskel FJ, Moore LC, Devarajan P:
Differential gene expression following early renal ischemia/reperfusion.
Kidney Int 2003, 63(5):1714–1724.
7. Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A: Accuracy
of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and
prognosis in acute kidney injury: a systematic review and meta-analysis.
Am J Kidney Dis 2009, 54(6):1012–1024.
8. Wheeler DS, Devarajan P, Ma Q, Harmon K, Monaco M, Cvijanovich N, Wong
HR: Serum neutrophil gelatinase-associated lipocalin (NGAL) as a marker
of acute kidney injury in critically ill children with septic shock. Crit Care
Med 2008, 36(4):1297–1303.
9. Shapiro NI, Trzeciak S, Hollander JE, Birkhahn R, Otero R, Osborn TM, Moretti
E, Nguyen HB, Gunnerson K, Milzman D, et al: The diagnostic accuracy of
Han et al. BMC Nephrology 2012, 13:25 Page 9 of 10
http://www.biomedcentral.com/1471-2369/13/25plasma neutrophil gelatinase-associated lipocalin in the prediction of
acute kidney injury in emergency department patients with suspected
sepsis. Ann Emerg Med, 56(1):52–59. e51.
10. Martensson J, Bell M, Oldner A, Xu S, Venge P, Martling CR: Neutrophil
gelatinase-associated lipocalin in adult septic patients with and without
acute kidney injury. Intensive Care Med, 36(8):1333–1340.
11. Ramesh G, Zhang B, Uematsu S, Akira S, Reeves WB: Endotoxin and
cisplatin synergistically induce renal dysfunction and cytokine
production in mice. Am J Physiol Renal Physiol 2007, 293(1):F325–332.
12. Zager RA, Johnson AC, Geballe A: Gentamicin suppresses endotoxin-
driven TNF-alpha production in human and mouse proximal tubule cells.
Am J Physiol Renal Physiol 2007, 293(4):F1373–1380.
13. Zager RA, Johnson AC, Lund S: Uremia impacts renal inflammatory
cytokine gene expression in the setting of experimental acute kidney
injury. Am J Physiol Renal Physiol 2009, 297:(4)F961–970.
14. Wang W, Bansal S, Falk S, Ljubanovic D, Schrier R: Ghrelin protects mice
against endotoxemia-induced acute kidney injury. Am J Physiol Renal
Physiol 2009, 297(4):F1032–1037.
15. Ramesh G, Kimball SR, Jefferson LS, Reeves WB: Endotoxin and cisplatin
synergistically stimulate TNF-alpha production by renal epithelial cells.
Am J Physiol Renal Physiol 2007, 292(2):F812–819.
16. Grigoryev DN, Liu M, Hassoun HT, Cheadle C, Barnes KC, Rabb H: The local
and systemic inflammatory transcriptome after acute kidney injury. J Am
Soc Nephrol 2008, 19(3):547–558.
17. Romanovsky AA, Ivanov AI, Shimansky YP: Selected contribution: ambient
temperature for experiments in rats: a new method for determining the
zone of thermal neutrality. J Appl Physiol 2002, 92(6):2667–2679.
18. Foglieni C, Fulgenzi A, Ticozzi P, Pellegatta F, Sciorati C, Belloni D, Ferrero E,
Ferrero ME: Protective effect of EDTA preadministration on renal
ischemia. BMC Nephrol 2006, 7:5.
19. Racusen LC: Alterations in tubular epithelial cell adhesion and
mechanisms of acute renal failure. Lab Invest 1992, 67(2):158–165.
20. Phillips TM: Measurement of total and bioactive interleukin-2 in tissue
samples by immunoaffinity-receptor affinity chromatography. Biomed
Chromatogr 1997, 11(4):200–204.
21. Chomczynski P, Sacchi N: The single-step method of RNA isolation by acid
guanidinium thiocyanate-phenol-chloroform extraction: twenty-
something years on. Nat Protoc 2006, 1(2):581–585.
22. Mori K, Lee HT, Rapoport D, Drexler IR, Foster K, Yang J, Schmidt-Ott KM,
Chen X, Li JY, Weiss S, et al: Endocytic delivery of lipocalin-siderophore-
iron complex rescues the kidney from ischemia-reperfusion injury. J Clin
Invest 2005, 115(3):610–621.
23. Wan L, Bagshaw SM, Langenberg C, Saotome T, May C, Bellomo R:
Pathophysiology of septic acute kidney injury: what do we really know?
Crit Care Med 2008, 36(4 Suppl):S198–203.
24. Hoste EA, Schurgers M: Epidemiology of acute kidney injury: how big is
the problem? Crit Care Med 2008, 36(4 Suppl):S146–151.
25. Urbschat A, Obermuller N, Haferkamp A: Biomarkers of kidney injury.
Biomarkers, 16(1):22–30.
26. Nguyen MT, Devarajan P: Biomarkers for the early detection of acute
kidney injury. Pediatr Nephrol 2008, 23(12):2151–2157.
27. Mishra J, Mori K, Ma Q, Kelly C, Yang J, Mitsnefes M, Barasch J, Devarajan P:
Amelioration of ischemic acute renal injury by neutrophil gelatinase-
associated lipocalin. J Am Soc Nephrol 2004, 15(12):3073–3082.
28. Mishra J, Ma Q, Kelly C, Mitsnefes M, Mori K, Barasch J, Devarajan P: Kidney
NGAL is a novel early marker of acute injury following transplantation.
Pediatr Nephrol 2006, 21(6):856–863.
29. Hall IE, Yarlagadda SG, Coca SG, Wang Z, Doshi M, Devarajan P, Han WK,
Marcus RJ, Parikh CR: IL-18 and urinary NGAL predict dialysis and
graft recovery after kidney transplantation. J Am Soc Nephrol, 21(1):
189–197.
30. Malyszko J, Malyszko JS, Mysliwiec M: Serum neutrophil gelatinase-
associated lipocalin correlates with kidney function in renal allograft
recipients. Clin Transplant 2009, 23(5):681–686.
31. Bataille A, Abbas S, Semoun O, Bourgeois E, Marie O, Bonnet F, Resche-
Rigon M, Abboud I, Losser MR, Jacob L: Plasma neutrophil gelatinase-
associated lipocalin in kidney transplantation and early renal function
prediction. Transplantation, 92(9):1024–1030.
32. Fu WJ, Li BL, Wang SB, Chen ML, Deng RT, Ye CQ, Liu L, Fang AJ, Xiong SL,
Wen S, et al: Changes of the tubular markers in type 2 diabetes mellitus
with glomerular hyperfiltration. Diabetes Res Clin Pract, : .33. Haase M, Haase-Fielitz A: [Acute kidney injury after cardiac surgery: Early
diagnosis with neutrophil gelatinase-associated lipocalin]. Med Klin
(Munich), 116(2):111–116.
34. Perrin C, Patard JJ, Jouan F, Collet N, Theoleyre S, Edeline J, Zerrouki S,
Laguerre B, Bellaud-Roturaud MA, Rioux-Leclercq N, et al: [The neutrophil
gelatinase-associated lipocalin, or LCN 2, marker of aggressiveness in
clear cell renal cell carcinoma]. Prog Urol, 21(12):851–858.
35. Atzori L, Mussap M, Noto A, Barberini L, Puddu M, Coni E, Murgia F, Lussu M,
Fanos V: Clinical metabolomics and urinary NGAL for the early prediction
of chronic kidney disease in healthy adults born ELBW. J Matern Fetal
Neonatal Med, 24(2):41–44.
36. Gaspari F, Cravedi P, Mandala M, Perico N, de Leon FR, Stucchi N, Ferrari S,
Labianca R, Remuzzi G, Ruggenenti P: Predicting cisplatin-induced acute
kidney injury by urinary neutrophil gelatinase-associated lipocalin
excretion: a pilot prospective case–control study. Nephron Clin Pract, 115
(2):154–160.
37. Mussap M, Noto A, Fravega M, Fanos V: Urine neutrophil gelatinase-
associated lipocalin (uNGAL) and netrin-1: are they effectively improving
the clinical management of sepsis-induced acute kidney injury (AKI)? J
Matern Fetal Neonatal Med, 24(2):16–18.
38. Bagshaw SM, Haase M, Haase-Fielitz A, Bennett M, Devarajan P, Bellomo R: A
prospective evaluation of urine microscopy in septic and non-septic
acute kidney injury. Nephrol Dial Transplant, : .
39. Bagshaw SM, Bennett M, Haase M, Haase-Fielitz A, Egi M, Morimatsu H,
D'Amico G, Goldsmith D, Devarajan P, Bellomo R: Plasma and urine
neutrophil gelatinase-associated lipocalin in septic versus non-septic
acute kidney injury in critical illness. Intensive Care Med, 36(3):452–461.
40. Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK:
The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes
with siderophore-mediated iron acquisition. Mol Cell 2002, 10(5):
1033–1043.
41. Fjaertoft G, Foucard T, Xu S, Venge P: Human neutrophil lipocalin (HNL) as
a diagnostic tool in children with acute infections: a study of the
kinetics. Acta Paediatr 2005, 94(6):661–666.
42. Bjorkqvist M, Kallman J, Fjaertoft G, Xu S, Venge P, Schollin J: Human
neutrophil lipocalin: normal levels and use as a marker for invasive
infection in the newborn. Acta Paediatr 2004, 93(4):534–539.
43. Liu Q, Nilsen-Hamilton M: Identification of a new acute phase protein.
J Biol Chem 1995, 270(38):22565–22570.
44. Tadesse S, Luo G, Park JS, Kim BJ, Snegovskikh VV, Zheng T, Hodgson EJ,
Arcuri F, Toti P, Parikh CR, et al: Intra-amniotic infection upregulates
neutrophil gelatinase-associated lipocalin (NGAL) expression at the
maternal-fetal interface at term: implications for infection-related
preterm birth. Reprod Sci, 18(8):713–722.
45. Zerega B, Cermelli S, Michelis B, Cancedda R, Cancedda FD: Expression of
NRL/NGAL (neu-related lipocalin/neutrophil gelatinase-associated
lipocalin) during mammalian embryonic development and in
inflammation. Eur J Cell Biol 2000, 79(3):165–172.
46. Nielsen BS, Borregaard N, Bundgaard JR, Timshel S, Sehested M, Kjeldsen L:
Induction of NGAL synthesis in epithelial cells of human colorectal
neoplasia and inflammatory bowel diseases. Gut 1996, 38(3):414–420.
47. Leoncini G, Mussap M, Viazzi F, Fravega M, Degrandi R, Bezante GP, Deferrari
G, Pontremoli R: Combined use of urinary neutrophil gelatinase-
associated lipocalin (uNGAL) and albumin as markers of early cardiac
damage in primary hypertension. Clin Chim Acta, 412(21–22):1951–1956.
48. Fassett RG, Robertson IK, Ball MJ, Geraghty DP, Cardinal JW, Coombes JS:
Effects of atorvastatin on NGAL and cystatin C in chronic kidney disease:
a post hoc analysis of the LORD trial. Nephrol Dial Transplant, : .
49. Bolignano D, Lacquaniti A, Coppolino G, Campo S, Arena A, Buemi M:
Neutrophil gelatinase-associated lipocalin reflects the severity of renal
impairment in subjects affected by chronic kidney disease. Kidney Blood
Press Res 2008, 31(4):255–258.
50. Paragas N, Qiu A, Zhang Q, Samstein B, Deng SX, Schmidt-Ott KM, Viltard M,
Yu W, Forster CS, Gong G, et al: The Ngal reporter mouse detects the
response of the kidney to injury in real time. Nat Med, 17(2):216–222.
51. Tracey KJ: Tumor necrosis factor (cachectin) in the biology of septic
shock syndrome. Circ Shock 1991, 35(2):123–128.
52. Molloy RG, Mannick JA, Rodrick ML: Cytokines, sepsis and
immunomodulation. Br J Surg 1993, 80(3):289–297.
53. Wu X, Guo R, Chen P, Wang Q, Cunningham PN: TNF induces caspase-
dependent inflammation in renal endothelial cells through a Rho- and
Han et al. BMC Nephrology 2012, 13:25 Page 10 of 10
http://www.biomedcentral.com/1471-2369/13/25myosin light chain kinase-dependent mechanism. Am J Physiol Renal
Physiol 2009, 297(2):F316–326.
54. Knotek M, Rogachev B, Wang W, Ecder T, Melnikov V, Gengaro PE, Esson M,
Edelstein CL, Dinarello CA, Schrier RW: Endotoxemic renal failure in mice:
Role of tumor necrosis factor independent of inducible nitric oxide
synthase. Kidney Int 2001, 59(6):2243–2249.
55. Cunningham PN, Dyanov HM, Park P, Wang J, Newell KA, Quigg RJ: Acute
renal failure in endotoxemia is caused by TNF acting directly on TNF
receptor-1 in kidney. J Immunol 2002, 168(11):5817–5823.
doi:10.1186/1471-2369-13-25
Cite this article as: Han et al.: Renal neutrophil gelatinase associated
lipocalin expression in lipopolysaccharide-induced acute kidney injury in
the rat. BMC Nephrology 2012 13:25.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
